期刊文献+

ExoSeal血管封堵器在急性缺血性脑卒中桥接治疗中的安全性和有效性

Safety and efficacy of ExoSeal vascular occluder in bridging therapy for acute ischemic stroke
下载PDF
导出
摘要 目的 探讨ExoSeal血管封堵器在接受桥接治疗的急性缺血性脑卒中(AIS)患者中的安全性和有效性。方法 回顾性分析2018年6月至2020年12月在潍坊市人民医院接受全量重组组织型纤溶酶原激活剂(rt-PA)溶栓后桥接血管腔内机械取栓治疗的142例AIS患者临床资料。所有患者在血管腔内机械取栓手术时均使用8 F股动脉鞘,术毕股动脉穿刺点由指压法封堵68例,7 F ExoSeal封堵器封堵74例。比较指压法组和封堵器组股动脉穿刺点封堵成功率及穿刺点相关并发症发生率。结果 封堵器组与指压法组相比,手术成功率显著增高(94.6%比83.8%,P=0.037)。指压法组、封堵器组患者术后至出院前分别有11例(16.2%)、4例(5.4%)发生穿刺点相关并发症(P=0.030),6例(8.8%)、2例(2.7%)发生深静脉血栓(P=0.109),均未发生动静脉瘘、假性动脉瘤、同侧下肢急性缺血、穿刺点相关大出血及需要血管外科手术或介入治疗的并发症。结论 ExoSeal封堵器可安全地应用于溶栓后桥接血管腔内机械取栓治疗的AIS患者,股动脉穿刺点封堵成功率较高,且降低穿刺点血肿发生率。 Objective To investigate the safety and efficacy of ExoSeal vascular occluder in bridging therapy for patients with acute ischemic stroke(AIS).Methods The clinical data of 142 AIS patients,who received mechanical thrombectomy in the bridge-connected vascular lumen after full dose recombinant tissue plasminogen activator(rt-PA) thrombolysis at the Weifang Municipal People's Hospital of China between June2018 and December 2020,were retrospectively analyzed.An 8-F femoral arterial sheath was used for the performance of endovascular mechanical thrombectomy in all patients.After the interventional procedure finished,the hemostasis of femoral artery puncture point was achieved by using manual compression(MC)method in 68 patients(MC group) and by using a 7-F ExoSeal vascular occluder method in 74 patients(ExoSeal group).The success rate of puncture point hemostasis and the incidence of puncture point-related complications were compared between the two methods.Results The success rate of surgery in the ExoSeal group was 94.6%,which was obviously higher than 83.8% in the MC group(P=0.037).During the period from the time of finishing surgery and the time of discharge,11 patients(16.2%) in the MC group and 4 patients(5.4%)in the ExoSeal group developed puncture point-related complications(P=0.030),and 6 patients(8.8%) in the MC group and 2 patients(2.7%) in the ExoSeal group developed deep vein thrombosis(P=0.109).No arteriovenous fistula,pseudoaneurysm,acute ischemia of the ipsilateral lower limb,puncture point-associated major bleeding,or other complications that required vascular surgery or interventional therapy occurred in all patients.Conclusion ExoSeal vascular closure device can be safely used in AIS patients who are receiving mechanical thrombectomy in the bridge-connected vascular lumen after thrombolysis.It carries high success rate for femoral artery puncture point hemostasis,besides,it can reduce the incidence of puncture point hematoma.
作者 刘涛 张纪存 张杰峰 刘继红 LIU Tao;ZHANG Jicun;ZHANG Jiefeng;LIU Jihong(Department of Vascular Surgery&Department of Rehabilitation,Weifang Municipal People's Hospital,Weifang,Shandong Province 261000,China)
出处 《介入放射学杂志》 CSCD 北大核心 2024年第2期122-125,共4页 Journal of Interventional Radiology
关键词 血管闭合装置 缺血性脑卒中 桥接治疗 并发症 vascular closure device ischemic stroke bridging therapy complication
  • 相关文献

参考文献4

二级参考文献103

  • 1Wahlgren N, Ahrced N, Davalos A, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet, 2007, 369: 275-282.
  • 2Lyden PD, ed. Thrombolytic Therapy for Acute Stroke. 2nd ed. Totowa, NJ: Hmreana Press, 2005.
  • 3Wardlaw JM, Smdercock PA, Berg: E. Throrrbolytic therapy with recoinbinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cunaflative meta-analysis. Stroke, 2003, 34: 1437-1442.
  • 4Wardlaw JM, Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev, 2003, (4): CD000213.
  • 5Shanna M, Clark H, Armour T, et al. Acute stroke: evaluation and treatment. Evid Rep Technol Assess (Sunmm), 2005, (127): 1-7.
  • 6Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Throrrbolysis for acute ischemic stroke: results of the Canadian Altephse for Stroke Effectiveness Study. CMAJ, 20(0, 172: 1307-1312.
  • 7Chung H, Refoios Canto R, Canto RR, et al. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart, 2007, 93: 1616-1617.
  • 8Saver JL, Smith EE, Fonarow GC, et al; GWTG-stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in > 30,000 patients ariving within 60 minutes of stroke onset. Stroke, 2010, 41: 1431-1439.
  • 9Scott PA, Xu Z, Meurer WJ, et al. Attitudes and beliefs of Michigan emergmcy physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke, 2010, 41: 2026-2032.
  • 10Kwiatkowski TG, Libman RB, Fmnkel M, et al. Effects of tissue plasrrfinogen activator for acute ischemic stroke at one year. National Institute of Neurological Disordeis and Stroke Recombinxaat Tissue Plasmiogen Activator Stroke Study Group. N Engl J Med, 1999, 340: 1781-1787.

共引文献1007

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部